Keystone Heart is focused on protecting the brain from emboli to reduce the risk of brain infarcts during TAVR, atrial fibrillation ablation and other structural heart procedures.

Latest News

Share this

Author: Keystone Heart

New Clinical Data Presented at EuroPCR Demonstrates that TriGuard Reduces Brain Lesion Volume during TAVR

New Clinical Data Presented at EuroPCR Demonstrates that TriGuard Reduces Brain Lesion Volume during TAVR. New clinical data presented from the DEFLECT-I study demonstrates that Keystone Heart’s TriGuard™ Cerebral Protection Device reduces brain lesion volume during TAVR (Transcatheter Aortic Valve Replacement) procedures when compared to historical...